Clinical Trials
We are dedicated to bringing the latest advances in tumor vaccines and immunotherapy to patients with cancer.
This goal is accomplished through clinical trials.
We conduct early Phase I studies of new agents through the National Cancer Institute, as well as Phase II and III clinical trials supported by pharmaceutical companies and the Southwest Oncology Group (SWOG), a national consortium of medical centers dedicated to bringing clinical trials to patients with all types of cancer.
Our staff includes a team of physicians, scientists, nurses, pharmacists, and social workers with expertise in the use of immunotherapy in patients with cancer.
The list of our active trials follows, but we recommend calling to get the most up to date information on our clinical trials program.
Colon Trials
- Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA-B7.1 Vaccine Administered with Chemotherapy, Alone or in Combination with Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients with Metastatic Colorectal Adenocarcinoma
Melanoma Trials
- A Phase I Trial of IntraLesional rV-TRICOM in the treatment of Maliganant Melanoma
- A Phase I Trial of IntraLesional rV-B7.1 Vaccine in the Treatment of Malignant Melanoma
- IntraLesional rF-B7.1 Versus rF-TRICOM in the Treatment of Metastatic Cancer
- A Phase III Multi-Institutional Randomization Study of Immunization with the gap 100:209:-217 (210M) Peptide Followed by High Dose IL-2 Versus High Dose IL-2 Alone in Patients with Metastatic Melanoma
- A Phase III Randomized Double-Bind Pivotal Trial of Immunotherapy with BCG plus a Polyvalent Melanoma Vaccine, Cancervax Versus BCG plus Placebo as a post surgical Treatment for Stage III Melanoma
- A Phase III Randomized Double-Bind Trial of Immunotherapy with Polyvalent Melanoma Vaccine, Cancervax plus BCG versus Placebo plus BCG as a post surgical Treatment for Stage IV Melanoma
Pancreas Trials
- An Open Label Phase I Study to Evaluate the Safety and Tolerability of rV-CEA(6D)/TRICOM Admixed with rV-MUC-1 Followed by rF-CEA(6D)/TRICOM in Combination with GM-CSF in Subjects with Unresectable Adenocarcinoma of the Pancreas
- An Open Label Phase I Study to Evaluate the Safety and Tolerability of PANVAC-VF in Combination with GM-CSF in Patients with Unresectable Adenocarcinoma of the Pancreas
Prostate Trials
- A Phase I Open Label Study to evaluate the Safety of PROSTVAC VF/TRICOM in the Treatment of Patients with Adenocarcinoma of the Prostate
- A Phase II Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC-VF/TRICOM in Combination with GM-CSF in Patients with Androgen-Independent Adenocarcinoma of the Prostate
Renal Cell Trials
- A preliminary study of the safety and immunogenicity of Trovax Vaccine given in conjunction with Interleukin-2 (IL-2) for the treatment of Stage IV Renal Cell Carcinoma
For more information regarding participation in one of our trials please contact Gail DeRaffele, RN, Clinical Coordinator at 212.342.0232 or gd2023@columbia.edu.
Links
|
